STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain

  • participants needed
  • sponsor
    M.D. Anderson Cancer Center
Updated on 20 September 2021
metastatic melanoma
metastatic disease
measurable disease
brain mri
neutrophil count
tumor cells
brain metastases
glioblastoma multiforme
malignant glioma
recurrent malignant glioma
seizure disorder
anaplastic glioma
immunologic adjuvant
cytotoxic t-lymphocyte antigen 4


This phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to the brain and is growing, spreading, or getting worse. STAT3 inhibitor WP1066 may stop the growth of tumor cells and modulate the immune system.


PRIMARY OBJECTIVES; I. Identify the maximum tolerated dose (MTD) of STAT3 inhibitor WP1066 (WP1066) in patients with recurrent malignant glioma (glioblastoma, anaplastic glioma), and melanoma patients with progressive brain metastasis.

II. Assess the safety and tolerability of WP1066 in patients with recurrent malignant glioma and melanoma patients with progressive brain metastasis using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) with special attention directed at determining whether any induced autoimmune reactions occur.


I. Pharmacokinetic analysis of the in vivo bioavailability of WP1066. II. Assess overall response rate (ORR) in patients with recurrent malignant gliomas and progressive metastatic melanoma to the brain.

III. Assess immunological response in patients with recurrent malignant glioma and melanoma patients with progressive brain metastasis treated with WP1066.

IV. Assess time to radiographically assessed progression and/or response in patients treated with WP1066.

V. Assess progression-free survival (PFS) and overall survival (OS) in patients treated with WP1066.

VI. Estimate the proportion of patients treated with WP1066 who develop additional melanoma metastatic lesions, including those in the central nervous system (CNS).

OUTLINE: This is a dose-escalation study.

Patients receive STAT3 inhibitor WP1066 orally (PO) twice daily (BID) on Monday, Wednesday, and Friday of weeks 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1 and 2 months.

Condition Central Nervous System Neoplasms, melanoma, skin cancer, Malignant neoplasm of brain, Metastatic Melanoma, Brain Tumor (Pediatric), Solid Tumors, Brain Metastasis, Recurrent Malignant Glioma, Metastatic Malignant Neoplasm in the Brain, Brain Metastases, Stage IV Melanoma, Recurrent Glioblastoma, Brain Cancer, Malignant Melanoma, Brain Tumor, recurrent brain tumors
Treatment laboratory biomarker analysis, Surgical Resection, pharmacological study, WP1066, Advanced Brain Tumor Imaging (ABTI), JAK2 Inhibitor WP1066, STAT3 Inhibitor WP1066
Clinical Study IdentifierNCT01904123
SponsorM.D. Anderson Cancer Center
Last Modified on20 September 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note